Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas?

Ju-Han Lee, Jun Won Um, Ji Hye Lee, Seo Hee Kim, Eung Seok Lee, Young Sik Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: To investigate 1) whether immunohistochemistry of multidrug-resistant (MDR) proteins (MDR1, MRP1, MRP2 and BCRP) in colorectal adenocarcinomas can substitute for histoculture drug response assays (HDRA) and 2) whether chemosensitivity as indicated by HDRA and MDR protein expression is related to prognostic parameters in colorectal cancers. Methodology: Chemosensitivity of cancer tissues to 5-FU, irinotecan and oxaliplatin was assessed by HDRA. Immunohistochemical staining of MDR proteins was quantified by image analysis in 76 colorectal adenocarcinoma patients. Results: Inhibition rates (IRs) of the anticancer drugs by HDRA were not related to MDR protein expression. However, the IR of 5-FU was significantly decreased with lymph node metastasis (p=0.03) and advanced clinical stages (p=0.047). The IRs of irinotecan and oxaliplatin were not associated with clinicopathological parameters. Immunohistochemically, positive scores for MRP2 and BCRP protein were paradoxically related to lower clinical stages (p=0.043) and male gender (p=0.019), respectively. Conclusions: Immunohistochemical staining of MDR proteins can not predict tumor responses to anticancer drugs in colorectal cancers. Chemoresistance to 5-FU as indicated by HDRA was highly associated with aggressive prognostic factors.

Original languageEnglish
Pages (from-to)1075-1078
Number of pages4
JournalHepato-Gastroenterology
Volume59
Issue number116
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Adenocarcinoma
Immunohistochemistry
oxaliplatin
irinotecan
Pharmaceutical Preparations
Fluorouracil
Proteins
Colorectal Neoplasms
Staining and Labeling
P-Glycoprotein
Neoplasms
Lymph Nodes
Neoplasm Metastasis

Keywords

  • Cancer
  • Chemosensitivity
  • Colon
  • Multidrug resistant

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

@article{a9a608da0ae24bafa578fd500b65991d,
title = "Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas?",
abstract = "Background/Aims: To investigate 1) whether immunohistochemistry of multidrug-resistant (MDR) proteins (MDR1, MRP1, MRP2 and BCRP) in colorectal adenocarcinomas can substitute for histoculture drug response assays (HDRA) and 2) whether chemosensitivity as indicated by HDRA and MDR protein expression is related to prognostic parameters in colorectal cancers. Methodology: Chemosensitivity of cancer tissues to 5-FU, irinotecan and oxaliplatin was assessed by HDRA. Immunohistochemical staining of MDR proteins was quantified by image analysis in 76 colorectal adenocarcinoma patients. Results: Inhibition rates (IRs) of the anticancer drugs by HDRA were not related to MDR protein expression. However, the IR of 5-FU was significantly decreased with lymph node metastasis (p=0.03) and advanced clinical stages (p=0.047). The IRs of irinotecan and oxaliplatin were not associated with clinicopathological parameters. Immunohistochemically, positive scores for MRP2 and BCRP protein were paradoxically related to lower clinical stages (p=0.043) and male gender (p=0.019), respectively. Conclusions: Immunohistochemical staining of MDR proteins can not predict tumor responses to anticancer drugs in colorectal cancers. Chemoresistance to 5-FU as indicated by HDRA was highly associated with aggressive prognostic factors.",
keywords = "Cancer, Chemosensitivity, Colon, Multidrug resistant",
author = "Ju-Han Lee and Um, {Jun Won} and Lee, {Ji Hye} and Kim, {Seo Hee} and Lee, {Eung Seok} and Kim, {Young Sik}",
year = "2012",
month = "6",
day = "1",
doi = "10.5754/hge09411",
language = "English",
volume = "59",
pages = "1075--1078",
journal = "Hepato-Gastroenterology",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "116",

}

TY - JOUR

T1 - Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas?

AU - Lee, Ju-Han

AU - Um, Jun Won

AU - Lee, Ji Hye

AU - Kim, Seo Hee

AU - Lee, Eung Seok

AU - Kim, Young Sik

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background/Aims: To investigate 1) whether immunohistochemistry of multidrug-resistant (MDR) proteins (MDR1, MRP1, MRP2 and BCRP) in colorectal adenocarcinomas can substitute for histoculture drug response assays (HDRA) and 2) whether chemosensitivity as indicated by HDRA and MDR protein expression is related to prognostic parameters in colorectal cancers. Methodology: Chemosensitivity of cancer tissues to 5-FU, irinotecan and oxaliplatin was assessed by HDRA. Immunohistochemical staining of MDR proteins was quantified by image analysis in 76 colorectal adenocarcinoma patients. Results: Inhibition rates (IRs) of the anticancer drugs by HDRA were not related to MDR protein expression. However, the IR of 5-FU was significantly decreased with lymph node metastasis (p=0.03) and advanced clinical stages (p=0.047). The IRs of irinotecan and oxaliplatin were not associated with clinicopathological parameters. Immunohistochemically, positive scores for MRP2 and BCRP protein were paradoxically related to lower clinical stages (p=0.043) and male gender (p=0.019), respectively. Conclusions: Immunohistochemical staining of MDR proteins can not predict tumor responses to anticancer drugs in colorectal cancers. Chemoresistance to 5-FU as indicated by HDRA was highly associated with aggressive prognostic factors.

AB - Background/Aims: To investigate 1) whether immunohistochemistry of multidrug-resistant (MDR) proteins (MDR1, MRP1, MRP2 and BCRP) in colorectal adenocarcinomas can substitute for histoculture drug response assays (HDRA) and 2) whether chemosensitivity as indicated by HDRA and MDR protein expression is related to prognostic parameters in colorectal cancers. Methodology: Chemosensitivity of cancer tissues to 5-FU, irinotecan and oxaliplatin was assessed by HDRA. Immunohistochemical staining of MDR proteins was quantified by image analysis in 76 colorectal adenocarcinoma patients. Results: Inhibition rates (IRs) of the anticancer drugs by HDRA were not related to MDR protein expression. However, the IR of 5-FU was significantly decreased with lymph node metastasis (p=0.03) and advanced clinical stages (p=0.047). The IRs of irinotecan and oxaliplatin were not associated with clinicopathological parameters. Immunohistochemically, positive scores for MRP2 and BCRP protein were paradoxically related to lower clinical stages (p=0.043) and male gender (p=0.019), respectively. Conclusions: Immunohistochemical staining of MDR proteins can not predict tumor responses to anticancer drugs in colorectal cancers. Chemoresistance to 5-FU as indicated by HDRA was highly associated with aggressive prognostic factors.

KW - Cancer

KW - Chemosensitivity

KW - Colon

KW - Multidrug resistant

UR - http://www.scopus.com/inward/record.url?scp=84861362815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861362815&partnerID=8YFLogxK

U2 - 10.5754/hge09411

DO - 10.5754/hge09411

M3 - Article

VL - 59

SP - 1075

EP - 1078

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

SN - 0172-6390

IS - 116

ER -